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Abstract Wilson’s disease (WD) is an autosomal recessive
disorder characterized by the functional disruption of adenosine
triphosphatase 7B (ATP7B), which results in positive copper
balance. Although the primary manifestations of the disease are
hepatic or neurological in scope, the factors that cause a very
diverse picture ofWD are not well researched.We compared the
first clinical presentation, ages of onset and diagnosis, copper
metabolism parameters, and ceruloplasmin levels between in-
dex cases (ICs) and their siblings. We examined 73 ICs and 95
siblings from 73 families, including a total of 168 patients with
biochemical and genetically confirmed WD diagnoses. We
observed an 86 % concordance rate of primary clinical symp-
toms among ICs with hepatic symptoms and their siblings.
There was 66 % concordance among ICs with neurological
symptoms and their siblings. No differences regarding age at
onset of symptoms or copper metabolism parameters at diagno-
sis were identified between hepatic ICs and their siblings. The
age at symptom onset did not differ between neurological ICs
and their siblings, although ICs presented lower ceruloplasmin
and serum copper levels. These results demonstrate a high intra-
familial concordance of the clinical and biochemical presenta-
tion of WD, suggesting that similar factors shared within the
same families strongly influence the disease presentation.
Introduction
Wilson’s disease (WD, OMIM: 277900), also referred to as
hepatolenticular degeneration, is a systemic disorder of
copper metabolism with an autosomal recessive mode of
inheritance. Hepatic or neurological symptoms are the pri-
mary manifestations. The estimated prevalence of WD is 1 in
7000 to 1 in 100,000, and gene carrier frequency is estimated
at more than 1 in 90 (Scheinberg and Sternlieb 1984; Olsson
et al 2000; Coffey et al 2013). Most patients develop initial
symptoms during the second and third decades of life.
The gene responsible for WD is located on chromosome
13, band q14.3 (13q14.3-q21.1). This gene encodes a
membrane-bound, copper-transporting P-type ATPase
(ATP7B, OMIM: 606882) that is crucial for the excretion
of copper by hepatocytes and its binding to ceruloplasmin.
Thus far, approximately 500 mutations of APT7B have been
identified. No direct genotype-phenotype correlation has
been proven regarding WD, as the data published to date
have shown somewhat conflicting results (Houwen et al
1995; Ha-Hao et al 1998; Stapelbroek et al 2004; Vrabelova
et al 2005; Gromadzka et al 2006). However, one consistent
finding suggests that patients with severe mutations (e.g.,
frameshift and nonsense mutations) present earlier onset of
the disease and more severe metabolic disturbances than
patients with missense mutations (Gromadzka et al 2005).
It is also clear that patients with the same mutations can
display different phenotypes (Deguti et al 2004; Gupta et al
2007). Therefore, it seems reasonable to assume that other
compound genetic interactions (other than APT7B muta-
tion), as well as epigenetic and environmental factors, may
play an important role in disease presentation (Deguti et al
2004; Das and Ray 2006; Gupta et al 2007; Behari and
Pardasani 2010; Litwin and Członkowska 2013).
To capture more precisely the influence of such factors, it
is reasonable to compare the clinical presentation of WD
among siblings from the same families, rather than in an
unrelated patient cohort (Santhosh et al 2008). Data from
published familial studies has been somewhat limited and
based on small numbers of cases, with inconsistent results
(Takeshita et al 2002; Vrabelova et al 2005; Santhosh et al
2008). It appears that even monozygotic twins can display
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completely different symptom patterns and ages of onset
(Członkowska et al 2009).
The aim of the present study was to evaluate the concor-
dance rate and compare the initial clinical and biochemical




After obtaining approval from the bioethical committee,
index cases (ICs) and their siblings with a confirmed diag-
nosis of WD and full clinical information (described below)
were identified from our registry of 609 patients. All of them
underwent clinical investigation and received a diagnosis of
WD at the Institute of Psychiatry and Neurology in Warsaw.
Diagnosis was based on clinical features, the presence of
Kayser-Fleischer rings, serum ceruloplasmin and copper
levels, and 24-h urine copper concentration. In most cases,
DNA analysis was performed and APT7B mutations were
identified according to the method described below.
The following data were included in the analysis:
– age at symptoms onset (first clinical signs strongly sug-
gestive of WD in symptomatic patients)
– clinical signs at onset: hepatic or neurological
– age at diagnosis
– biochemical parameters at diagnosis, including serum
ceruloplasmin, serum copper, and copper concentration
in a 24-h urine sample
– mutation status of the carrier
All ICs were divided into two main groups based on their
initial predominant symptoms of WD (i.e., hepatic or neuro-
logical) according to the phenotypic classification of
Wilson’s disease proposed by Ferenci et al in 2003. Siblings
were similarly grouped or recognized as presymptomatic
(i.e., without signs, symptoms, or laboratory findings
suggestive of WD) prior to diagnosis. Hepatic signs and
symptoms included abdominal pain, jaundice, ascites,
acute/chronic liver failure, hemostatic disturbance, history
of hemolytic anemia, and abnormal liver tests. Neurological
signs and symptoms included tremor, dystonia, speech, fa-
cial expression, gait disturbances, and ataxia, as well as
neuropsychiatric disturbances like mood, emotional and be-
havioral control imbalance, and frank psychosis.
Dividing main groups of patients into subgroups according
to the mutation status of the ICs and siblings resulted in patient
populations that were too small for genotype-phenotype
analysis. Therefore, only basic genetic data was analyzed by
subgroup.
Laboratory examinations
Serum ceruloplasmin levels were measured using the im-
proved colorimetric enzymatic assay developed by Ravin
(1961). Serum copper concentration and 24-h urinary copper
excretion were measured using flame atomic absorption
spectrometry (FAAS). ATP7B genotyping was performed
using polymerase chain reaction restriction fragment length
polymorphism analysis and/or direct ATP7B gene sequenc-
ing, as described previously (Gromadzka et al 2005, 2006).
Statistics
Variables are reported as means and 95 % confidence intervals
(95 % CIs), and were compared between groups using the
Mann Whitney U test, analyzed with SPSS Statistics 17.0
software. Values of p<0.05 were considered statistically
significant.
Between-group comparison
To calculate the concordance rate, we employed the
proband- or case-wise concordance rate, judging the propor-
tion of individuals with the same trait—here, the first disease
manifestation among ICs and their siblings (Smith 1974).
The following formula was used in this estimation: Case-
wise concordance (Cc)=2C/(2C+D), where C is the number
of concordant siblings and D is the number of discordant
pairs (McGue 1992).
Results
We identified 73 ICs with 95 siblings for analysis. Among
ICs, 30 patients (41 %) exhibited predominantly hepatic WD
and 43 (59 %) exhibited predominantly neurological WD
symptoms at onset.
In the group of 30 ICs with hepatic presentation at onset,
there were 21 ICs with 24 siblings that were also symptom-
atic: 18 (75 %) had hepatic signs and symptoms, six (25 %)
had neurological initial manifestation of the disease, and 11
were presymptomatic. Therefore, according to the employed
formula (see Methods), there was an 86 % rate of concor-
dance of initial signs and symptoms at onset in this group.
We observed no significant differences between hepatic ICs
and their respective symptomatic siblings regarding age at
onset, age at diagnosis, ceruloplasmin level, serum cop-
per concentration, or 24-h urine copper concentration.
We also observed no differences between the hepatic
ICs and any of their symptomatic or presymptomatic
siblings regarding age at diagnosis, ceruloplasmin and
serum copper levels, or 24-h urine copper concentration
(Table 1).
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In the group of 43 ICs with neurological initial symptoms,
we identified 24 ICs with 28 symptomatic siblings: 14 had
neurological and 14 had hepatic manifestations at onset.
Thirty-two siblings were presymptomatic at the time of
diagnosis. This finding constitutes a 66 % concordance rate
of initial clinical presentation among neurological ICs
and their symptomatic siblings. Although there were no
differences between neurological ICs and their symp-
tomatic siblings regarding the age of onset or the age
of diagnosis, in this case ICs presented significantly
lower ceruloplasmin (p=0.004) and serum copper con-
centration (p=0.001).
When all neurological ICs were compared with all symp-
tomatic and presymptomatic siblings, we observed no dif-
ferences regarding age at diagnosis; however, neurological
ICs presented significantly lower ceruloplasmin and serum
copper concentration levels (Table 2).
Genetic analysis
Among hepatic ICs and their symptomatic siblings with
analyzed ATP7B mutations, the most frequent mutation
was H1069Q (c.3207C>A), with an allelic frequency of
77 %. In this group, 32 patients altogether had missense
mutations in both ATP7B alleles, and eight patients
(20 %) were compound heterozygotes possessing the
H1069Q mutation on one allele and a severe (i.e.,
nonsense or frameshift) mutation on the second ATP7B
allele.
In the group of neurological ICs and their symptomatic
siblings with analyzed ATP7B mutations, the H1069Q mu-
tation reached an allelic frequency of 73.5 %. Twenty-one
patients altogether (68 %) had a missense mutation on both
ATP7B alleles. Ten individuals (32 %) were compound
heterozygotes possessing a missense mutation on one
ATP7B allele and a severe mutation on the other allele
(Table 3).
Aside from H1069Q, the most frequent missense mutations
included T997M (c.2930T>C), T1220M (c.3659C>T), S653Y
(c.1958C>A), and G988R (c.2962G>C). Among severe muta-
tions, the T997M (c.2930T>C), T1220M (c.3659C>T), S653Y
(c.1958C>A), and G988R (c.2962G>C) were identified.
Concordance rates and further comparisons were not
evaluated because the numbers of patients were too small
when patients were assigned to subgroups according to each
carrier’s mutation status.
Table 1 Clinical and biochemical characteristics of index cases (ICs) with hepatic signs at onset and their siblings




N 30 35 18 6 11
Age at onset, years 23.1 (19.7–26.5) NA 24.2 (17.8–30.5) 25.7 (16.5–34.8) NA
Age at diagnosis, years 25.2 (21.7–28.6) 26.0 (22.3–29.8) 27.6 (21.5–30.6) 28.7 (19.4–37.9) 22.0 (17.1–26.8)
Ceruloplasmin, mg/dl 11.7 (9.4–14.1) 11.5 (9.6–13.4) 11.8 (9.1–14.4) 7.5 (3.8–11.3) 11.5 (7.9–15.1)
Serum Cu, μg/dl 56.9 (46.8–67.1) 51.3 (42.2–60.4) 52.0 (39.5–64.4) 50.0 (23.8–76.3) 50.9 (27.8–74.0)
Urinary Cu, μg/24 h 181.4 (111.1–251.8) 154.7 (88.0–221.5) 111.6 (82.6–140.5) 105.2 (47.3–257.8) 90.0 (58.0–122.0)
Data are presented as mean (95 % CI). Laboratory norms: ceruloplasmin: 25–45 mg/dl, serum copper: 70–140 μg/dl, urinary copper: 0–50 μg/24 h
NA not applicable
Table 2 Clinical and biochemical characteristics of index cases (ICs) with neurological signs at onset and their siblings
Group All neurological
ICs




N 43 60 14 14 32
Age at onset, years 25.3 (23.3–27.2) NA 23.7 (17.2–30.2) 27.2 (23.1–32.3) NA
Age at diagnosis, years 26.1 (24.3–27.8) 27.2 (24.6–29.9) 29.2 (22.6–35.8) 28.3 (24.0–32.7) 25.9 (21.9–29.9)
Ceruloplasmin, mg/dl 10.7* (8.8–12.6) 16.8* (14.8–18.9) 17.0 (11.7–22.3) 17.6 (12.9–22.2) 16.1 (13.4–18.8)
Serum Cu, μg/dl 32.2** (25.1–39.3) 48.8** (43.1–54.3) 54.8 (39.6–69.9) 50.0 (36.1–64.0) 45.3 (38.9–51.8)






Data are presented as mean (95 % CI). Laboratory norms: ceruloplasmin: 25–45 mg/dl, serum copper: 70–140 μg/dl, urinary copper: 0–50 μg/24 h
NA not applicable
*p<0.001; **p<0.001
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Discussion
Our data revealed an impressive 86 % concordance rate of
clinical symptoms between hepatic ICs and their symptomatic
siblings at the time of disease onset, and a 66 % concordance
rate of clinical symptoms between neurological ICs and their
siblings. These results suggest that members of the same
family may have very similar phenotypic presentation of
WD. These high concordance rates may reflect the influence
of inherited genetic similarities (including, but not limited to,
the ATP7B mutation) and environmental factors that are
shared within the same family and influence affected siblings
to a comparable degree and for a comparable period of time.
Conversely, less than 100 % concordance may reflect the
influence of other non-shared environmental and genetic com-
ponents, owing to complex individual differences.
There are other autosomal recessive disorders that lack any
clear-cut genotype-phenotype correlations, in which other ge-
netic and non-genetic factors are considered to have substantial
phenotype-modifying effects (Scriver andWaters 1999; Burke
2003; Rankin et al. 2008). In WD, other genetic factors pre-
sumed to influence the phenotype include allele status and the
mutations of methyltetrahydrofolate reductase (Gromadzka
et al 2011), prion-related protein (PrP) (Merle et al 2006),
interleukin-1 receptor antagonist (Gromadzka and
Członkowska 2011), or apolipoprotein E genes (Schiefermeier
et al 2000; Litwin et al 2012). Individual differences in hepatic
copper metabolism, tolerance to copper toxicity, and allelic
dominance mechanisms are considered as main determinants
of intra-familial diversity in WD (Takeshita et al 2002).
Slightly higher concordance between hepatic ICs and
their symptomatic siblings versus neurological ICs and their
siblings can be partly explained by the primary principles of
copper metabolism, since the liver is the first organ in which
copper accumulates and is especially prone to damage
caused by copper overload (Linder et al 1998).
Neurological presentation appears to be more complicat-
ed and less predictable, given that there are more complex
interactions between copper and ceruloplasmin and the cen-
tral nervous system. First, copper serves as a cofactor and a
modulator of enzymes that are crucial for brain homeostasis,
such as superoxide dismutase and dopamine hydroxylase.
Copper is also centrally involved in iron transport (Cox and
Moore 2002) and myelination processes (Prodan et al 2002).
Additionally, brain-specific amyloid precursor protein and
PrP are copper-binding, copper-dependent proteins that have
important roles in neurodegeneration (Multhaup et al 1996;
Millhauser 2004). Ceruloplasmin itself is involved in the trans-
port of other metal ions and possesses very strong antioxidant
properties, such as ferroxidase activity (Gutteridge 1978).
Therefore, reduced ceruloplasmin levels may reflect an in-
creased level of oxidative stress. In conclusion, high
intrafamilial concordance rates of clinical and biochemical
presentation ofWD revealed among siblings shall be a premise
for further research regarding the influence of epigenetic,
environmental, and other genetic factors.
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